Page 88 - Mesenchymal Stem cells, Exosomes and vitamins in the fight aginst COVID

Intravascular Mesenchymal Stem Cells to Treat Organ Failure and Possible Application in COVID-19

Improvement in LVEDV, LVESV, systolic wall thickening in the infarct zone, and border zone. No change in SV, CO, CI, ventricular mass index and late contrast enhancement. MSC infusion during CABG. No change in myocardial viability and perfusion, LVEF, LVEDV, LVESV, death, recurrent MI, and rehospitalization. One patient report of coronary occlusion during MSC infusion treated with tirofiban and Improvement in LVEF. No significant differen

Findings balloon inflation. after MI. rehospitalization.

Follow- Up 12 24 6 6 18 24 6

LVEF Impact Not assessed No Yes - improvement Yes - improvement Yes - improvement Yes - improvement No

Outcome Yes No Yes Yes Yes Yes No

Condition IHD IHD IHD HF HF IHD IHD

Delivery Method CABG IC IC IC IC IC IC

Type of Stem Cell BM MNC BM MSC BM MSC UC MSC UC MSC UC MSC BM MNC

Number of SCs 133 million 3 million [Pas 2] 72 million [Pas 4–5] Not disclosed 6 million [Pas 3] 3, 4, 5 million 200–500 million

Table 2 con't. MSC therapy studies treating cardiac failure.
BMA (mL) 60 80 20–25 Not disclosed NA NA 100–150

No. of Patients in Treatment Group 31 21 33 30 58 15 109

Type of Study RCT RCT RCT RCT RCT Case series Controlled trial

Year 2013 2013 2014 2015 2015 2015 2015

Author Lu et al, Int J Cardiology 2013; 168:2221-2227 Gao et al, Int J Cardiol 2013; 168:3191-3199 Lee et al, J Korean Med Sci 2014; 29:23-31 Zhao et al, Genet Mol Res 2015; 14:3010-3017 Gao et al, BMC Medicine 2015; 13:162 Li et al, Curr Pharm Des 2015; 21:1426-1432 Nair et al, Indian J Med Res 2015; 142:165-174

www.painphysicianjournal.com S405